Scheme

quant Healthcare Fund

Holds 13 companies worth ₹286 Cr in Sept 2026.

Fund house
QUANTThe fund house that runs this scheme.
AUM
₹431 Crquant Healthcare Fund's AUM at the end of 30 Sept 2026, as AMFI reports it. Up 0.7% on Aug 2026, ₹428 Cr.
Largest holding
GLAXO SMITHKLINE PHARMAGLAXO SMITHKLINE PHARMA is 9.7% of this scheme's NAV.
Fund manager
Sandeep TandonRuns it since 17 Jul 2023, as the fund house dates it. With Ankit Pande (co-manager), Sanjeev Sharma (co-manager), Varun Pattani (co-manager), Sameer Kate (co-manager), Yug Tibrewal (co-manager), Ayusha Kumbhat (co-manager).

Holdings^{(Aug 2023 – Sept 2026)}

Holdings in Sept 2026. Tick up to 2 to plot them.
Plot	13 companies ·	₹ Cr
	GLAXO SMITHKLINE PHARMA	41.1
	Cadila Healthcare	39.9
	Strides Arcolab	38.4
	Pfizer	31.3
	Alivus Life Sciences	26.4
	IPCA Laboratories Limited	25.4
	Aurobindo Pharma	21.6
	Zydus Wellness Limited	20.8
	Colgate Palmolive I Ltd	14.6
	Natco Pharma	12.8
	Dr Reddy s Laboratories Limited	9.9
	LG Electronics Inc	2.5
	Heubach Colorants India Limited	1.1

Fig. 1.Market value of each ticked company in quant Healthcare Fund, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.

Fig. 2.This scheme's holdings, by market cap, by sector and by company. Hover a slice or a row; click a slice to open it.

Fig. 3.Change in market value since the previous month, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.

Every holding in Sept 2026: its shares, market value (₹ crore) and % of NAV. Month end. Source: AMC monthly portfolio disclosures. Click a column's header to sort by it.

GLAXO SMITHKLINE PHARMA	Equity	Pharmaceuticals & Biotechnology	1.49L	41.1	9.69
Divi s Laboratories Ltd Future	F&O		43.8K	40.9	9.63
Cadila Healthcare	Equity	Pharmaceuticals & Biotechnology	3.43L	39.9	9.39
Glenmark Pharmaceuticals Ltd Future	F&O		1.68L	39.6	9.34
Strides Arcolab	Equity	Pharmaceuticals & Biotechnology	3.43L	38.4	9.04
Torrent Pharmaceuticals Ltd Future	F&O		75.8K	36.6	8.62
Pfizer	Equity	Pharmaceuticals & Biotechnology	80.7K	31.3	7.37
Alivus Life Sciences	Equity	Pharmaceuticals & Biotechnology	1.91L	26.4	6.21
IPCA Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	1.32L	25.4	5.98
Aurobindo Pharma	Equity	Pharmaceuticals & Biotechnology	1.29L	21.6	5.09
Zydus Wellness Limited	Equity	Food Products	4.05L	20.8	4.90
Aurobindo Pharma Ltd Future	F&O		1.14L	19.2	4.52
Colgate Palmolive I Ltd	Equity	Personal Products	83.1K	14.6	3.45
Natco Pharma	Equity	Pharmaceuticals & Biotechnology	1.55L	12.8	3.01
Dr Reddy s Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	80.3K	9.9	2.33
LG Electronics Inc	Equity	Consumer Durables	14.6K	2.5	0.59
Heubach Colorants India Limited	Equity	Chemicals & Petrochemicals	25.5K	1.1	0.26

Fig. 4.Every holding in Sept 2026: its shares, market value (₹ crore) and % of NAV. Month end. Source: AMC monthly portfolio disclosures.